Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by autoantibodies against a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Uncleaved von Willebrand factor (VWF) multimers accumulate and bind to platelets which causes spontaneous microt...
Main Authors: | Manu R. Pandey, Pankit Vachhani, Evelena P. Ontiveros |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2017-01-01
|
Series: | Case Reports in Hematology |
Online Access: | http://dx.doi.org/10.1155/2017/9681832 |
Similar Items
-
Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01) -
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
by: Jae-Sook Ahn, et al.
Published: (2014-01-01) -
Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
by: Claudio Cerchione, et al.
Published: (2016-01-01) -
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01) -
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
by: Jatin J Shah, et al.
Published: (2009-01-01)